Advanced Bladder Cancer COE - Results from #120

REVIEW UroToday

Advanced Bladder Cancer COE

Search

Antibody-drug Conjugate (ADC) Sacituzumab Govitecan in Metastatic UroThelial Carcinoma - Scott Tagawa Details Scott Tagawa discusses his recent research on the use of antibody-drug conjugate (ADC) sacituzumab govitecan in advanced metastatic urothelial carcinoma. The primary endpoint of the study was the objective response rate and the results of the Phase 2 subset were presented at ASCO GU 2019. The responses were seen with reasonable drug tolerance, a manageable and predictable safety profile, and a rel...
Joshua J. Meeks on SWOG 1806 Study Details Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...
Advances in Bladder Cancer Beyond Immunotherapy and Checkpoint Inhibitors - Evan Yu Details (Length of Discussion: 9 min) Evan Yu and Alicia Morgans have a diverse conversation highlighting the advances in the field of bladder cancer beyond IO and Checkpoint inhibition. They introduce a variety of therapy options being studied such as FGFR inhibition, antibody-drug conjugates, HER-2 and DNA repair. Biographies: Evan Yu, MD Alicia Morgans, MD Referenced in this discussion: Targeted Therap...
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials -Pedro Barata Details (Length of Discussion: 21 min) Petros Grivas and Pedro Barata discuss how a recent study they performed applies to the field of metastatic urothelial cancer regarding the use of checkpoint inhibitors in a patient population outside the context of the clinical trial and the main objectives, results, and conclusion of that study as well as implications for the field. Biographies: Pedro Barata, MD, M...
The State of Advanced Bladder Cancer - New Data from AACR 2018 - Interview with Arjun Balar Details (Length of Discussion: 30 min) Arjun Balar, MD overviews his presentation from the American Association for Cancer Research Annual Meeting (AACR 2018) meeting on durvalumab plus tremelimumab, combination data in patients with metastatic urothelial cancer. A phase I, Study 10, of data which shows clinical activity with combination treatment in 2nd-line metastatic urothelial carcinoma. A study desig...